Biotech stocks took a hit after President Trump’s tariff comments spooked investors harder than a surprise lab result. Amgen led the sector’s dip with a 2.39% drop, while Regeneron and Merck also slid ...

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...

Shares of Regeneron Pharmaceuticals Inc. slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...

In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025) ...

On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...